Defender Pharmaceuticals
Defender Pharmaceuticals is a privately held life sciences company dedicated to discovering, developing, and commercializing medicines to safeguard health across civilian and military populations. They focus on innovative therapies, including intranasal scopolamine, to treat conditions such as motion sickness, depression, and other health challenges, with collaborations involving NASA, the U.S. Navy, and the Department of Veterans Affairs.
Industries
Nr. of Employees
small (1-50)
Defender Pharmaceuticals
Products
Intranasal scopolamine nasal gel (investigational)
An investigational intranasal gel formulation of scopolamine developed to prevent nausea and vomiting induced by motion; assessed in Phase 2 and Phase 3 clinical studies and submitted for regulatory review.
Intranasal Scopolamine Motion Sickness Product
An innovative intranasal delivery system administering scopolamine to provide rapid absorption and fast-acting relief from symptoms associated with motion sickness.
DPI-386
DPI-386 is an investigational compound combining a novel scopolamine formulation with innovative intranasal delivery technology, in development for the prevention of symptoms associated with motion sickness.
Intranasal scopolamine nasal gel (investigational)
An investigational intranasal gel formulation of scopolamine developed to prevent nausea and vomiting induced by motion; assessed in Phase 2 and Phase 3 clinical studies and submitted for regulatory review.
Intranasal Scopolamine Motion Sickness Product
An innovative intranasal delivery system administering scopolamine to provide rapid absorption and fast-acting relief from symptoms associated with motion sickness.
DPI-386
DPI-386 is an investigational compound combining a novel scopolamine formulation with innovative intranasal delivery technology, in development for the prevention of symptoms associated with motion sickness.
Services
Sponsor-led partnerships to design and run clinical studies in collaboration with government agencies and research institutions to evaluate intranasal therapeutics in both simulated and operational environments.
Preparation and management of regulatory filings and formal communications with regulatory agencies, including responding to review decisions and planning remediation.
Execution of exclusive license agreements and coordination of transfers of IND materials, dossiers, and biologicals from government laboratories to support downstream development and commercialization.
Structured intake and response process for healthcare professional and public inquiries about investigational products via a medical information request form.
Sponsor-led partnerships to design and run clinical studies in collaboration with government agencies and research institutions to evaluate intranasal therapeutics in both simulated and operational environments.
Preparation and management of regulatory filings and formal communications with regulatory agencies, including responding to review decisions and planning remediation.
Execution of exclusive license agreements and coordination of transfers of IND materials, dossiers, and biologicals from government laboratories to support downstream development and commercialization.
Structured intake and response process for healthcare professional and public inquiries about investigational products via a medical information request form.
Expertise Areas
- Intranasal drug delivery
- Clinical trial management (Phase 2–3)
- Pharmacokinetic studies
- Regulatory submissions and agency interactions (NDA lifecycle)
Key Technologies
- Intranasal gel drug delivery
- Pharmacokinetic analysis
- Randomized double-blind placebo-controlled trials
- Cross-over trial design